OncoMatch/Clinical Trials/NCT06389760
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Is NCT06389760 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nimotuzumab and mFOLFIRINOX for pancreatic cancer.
Treatment: Nimotuzumab · mFOLFIRINOX · GX — This is a prospective, multicenter, single-arm, open-label study. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX/GX for postoperative adjuvant treatment of pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Prior systemic anti-tumor therapy, such as chemotherapy, radiotherapy
Lab requirements
Blood counts
White blood cells (WBC) ≥ 3.0×10^9/L; absolute neutrophil count (ANC) ≥ 1.5×10^9/L; hemoglobin ≥ 9.0 g/dL; platelets ≥ 75×10^9/L
Kidney function
serum creatinine ≤ 1×ULN or estimated creatinine clearance ≥ 50 mL/min
Liver function
serum total bilirubin (TBIL) ≤ 1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Adequate organ and bone marrow function, defined as follows: White blood cells (WBC) ≥ 3.0×10^9/L; absolute neutrophil count (ANC)≥1.5×10^9/L; hemoglobin≥9.0 g/dL; platelets≥75×10^9/L; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1×ULN or estimated creatinine clearance ≥ 50 mL/min; Left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06389760 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages